Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 1:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 4,271 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ADM Clear all

Conditions: Tobacco Use Disorder, HIV
Interventions: PSFW+, AHA, Nicotine polacrilex; Behavioral · Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Baltimore, Maryland • The Bronx, New York

Conditions: Breast Cancer, Cardiotoxicity, Drug-Related Side Effects and Adverse Reactions, Cardiovascular Diseases
Interventions: Social Determinants of Health; Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2039
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Predictive Cancer Model
Interventions: Liver Risk Computation Model (LIRIC), Liver Risk Computation Model (LIRIC)_cirrhosis, Liver Risk Computation Model (LIRIC)_no_cirrhosis; Other
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 40 Years to 100 Years
Enrollment: 6,000,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Depression, Anxiety, Engagement, Patient
Interventions: IntelliCare, Psychoeducation, Coaching; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older · Female only
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Lymphoma, Non-Hodgkin
Interventions: Venetoclax, Cyclophosphamide, Obinutuzumab, Rituximab, Doxorubicin, Vincristine, Prednisone; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 9
States / cities: Fullerton, California • Los Angeles, California • Santa Maria, California + 6 more

Conditions: Chlamydia, Gonorrhea, HIV
Interventions: HIV testing, STI/HIV-T, STI/HIV-Plus; Behavioral
Lead sponsor: North Bronx Healthcare Network; Other
Eligibility: 14 Years to 21 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Mantle Cell Lymphoma
Interventions: Acalabrutinib, Bortezomib, Cyclophosphamide, Cytarabine, Doxorubicin Hydrochloride, Prednisone, Rituximab, Rituximab and Hyaluronidase Human; Drug · Biological
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years to 75 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 3
States / cities: New York, New York • Charlotte, North Carolina • Seattle, Washington

Conditions: Osteoarthritis, Hip
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: Stanford, California

Conditions: Spinal Cord Injury
Interventions: Multi-Family Group Treatment, SCI Education Control Group; Behavioral
Lead sponsor: St. Luke's Rehabilitation Institute; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Gingival Recession
Interventions: Allograft Material ADM-S, Allograft Material ADM-D; Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 89 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Breast Cancer
Interventions: Ixabepilone, Paclitaxel, Cyclophosphamide, Doxorubicin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 384 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 10
States / cities: Palm Springs, California • Coral Spring, Florida • Davie, Florida + 7 more

Conditions: Stroke Acute
Interventions: Endovascular Therapy (Mechanical Thrombectomy), Standard Medical Management; Other
Lead sponsor: Santiago Ortega Gutierrez; Other
Eligibility: 18 Years to 80 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Major Depressive Disorder, Depression, Mood Disorders, Suicidal Ideation
Interventions: Nitrous Oxide, Placebo gas; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions: Laboratory Biomarker Analysis, PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1, Pegylated Liposomal Doxorubicin Hydrochloride; Other · Biological · Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 7
States / cities: Birmingham, Alabama • Orange, California • St Louis, Missouri + 4 more

Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions: Biospecimen Collection, Breast Biopsy Procedure, Carboplatin, Cyclophosphamide, Darolutamide, Doxorubicin, Epirubicin, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab, Surgical Procedure, Ultrasound Imaging; Procedure · Drug · Biological
Lead sponsor: Vandana Abramson; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hyperglycemia
Interventions: Sitagliptin, Placebo, Supplemental insulin (insulin lispro), Supplemental insulin (insulin aspart), Long acting basal insulin (insulin detemir), Long acting basal insulin (insulin glargine); Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Cancer Survivors, African Americans, Women, Psychology, Positive, Cardiometabolic Syndrome, Exercise, Feasibility Studies, Breast Neoplasm Female
Interventions: Gratitude Intervention; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 50 Years to 99 Years · Female only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Ann Arbor Stage IV Marginal Zone Lymphoma, Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Indolent Non-Hodgkin Lymphoma
Interventions: Cyclophosphamide, Doxorubicin Hydrochloride, Parsaclisib, Pegfilgrastim, Polatuzumab Vedotin, Prednisone, Rituximab, Vincristine Sulfate; Drug · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: ADHD, Depression Disorders, Mood Disorders, Anxiety Disorder Generalized, Bipolar Disorder (BPD)
Interventions: Prescription Psychotropic Medications; Drug
Lead sponsor: Gaize; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Rare Diseases, Autism or Autistic Traits, Development Delay, SYT-SSX Fusion Protein Expression, Sleep Disorder, Epilepsy, Generalized, Motor Delay
Interventions: Brain Magnetic Resonance Imaging (MRI), Whole Genome Sequencing, Induced Pluripotential Stem Cells; Diagnostic Test · Genetic · Other
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 0 Years to 99 Years
Enrollment: 50 participants
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Fracture, Pain, Postoperative
Interventions: Methadone, Morphine; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Mild Cognitive Impairment, Diabetes
Interventions: Diabetes Regulation for Eyesight and Memory, Enhanced Usual Care; Behavioral
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 65 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Richter Syndrome, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma, Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions: Biospecimen Collection, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Multigated Acquisition Scan, Pirtobrutinib, Positron Emission Tomography, Prednisone, Rituximab, Rituximab and Hyaluronidase Human, Survey Administration, Vincristine; Procedure · Drug · Biological + 1 more
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2036
U.S. locations: 62
States / cities: Irvine, California • Laguna Hills, California • Orange, California + 48 more

Conditions: Delirium
Interventions: Cognitive test + Pupillary measure; Combination Product
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 325 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Atlanta, Georgia

Search by objective public record fields.

RCT of an Internet Cessation Program Plus Online Social Network for HIV+ Smokers

Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Breast Cancer

Prospective Validation of Liver Cancer Risk Computation (LIRIC) Models

Mobile Apps to Reduce Distress in Breast Cancer Survivors Using an Adaptive Design

A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL

Project AWARE: Using the Emergency Department (ED) to Prevent Sexually Transmitted Infections (STIs) in Youth

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

Measured Hypocretin Levels and Recovery After Hip Surgery

Comparison of Two Psycho-educational Family Group Interventions for Persons With SCI and Their Caregivers

Gingival Augmentation and Root Coverage With Superficial and Deep Cut Acellular Dermal Matrices

Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer

EnDOvascular Therapy for Late WiNdow IschEmic Stroke Patients Selected bY AutoMatic Plain ComputErized Tomography

Nitrous Oxide- Suicidal Ideation

EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

Sitagliptin in Non-Diabetic Patients Undergoing General Surgery

Grateful Strides Toward Physical Activity and Well-Being for Black Breast Cancer Survivors

Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

Evaluate the Effects of Long-term Use of Psychotropic Medications on Eye Movement Patterns With the Gaize Device

Baker Gordon Syndrome Natural History Study

Methadone Versus Morphine for Orthopedic Surgery Patients

Health Beliefs, Glycemic Control, and Preventing Cognitive Decline in African Americans with Diabetes and Mild Cognitive Impairment: a Randomized Clinical Trial

Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial

Clinical Investigation of an Eye-Tracking Device as a Predictor of Delirium in the Recovery Room After Surgery With General Anesthesia